Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MPL | P40238 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18094535 | 0.86 | MAPT (0.44) | MAPTADORA3RXFP1MPLLMNA | |
| SCHEMBL18094573 | 0.86 | ADORA3 (0.53) | MAPTADORA3NPC1RAB9ATP53 | |
| SCHEMBL18094473 | 0.86 | KDM4E (0.45) | MAPTADORA3RXFP1MPLLMNA | |
| SCHEMBL18094520 | 0.86 | MPL (0.45) | MAPTADORA3RXFP1MPLLMNA | |
| SCHEMBL18094532 | 0.85 | TRPV1 (0.45) | MAPTADORA3RXFP1MPLLMNA | |
| SCHEMBL18094539 | 0.84 | ADORA3 (0.58) | MAPTADORA3RXFP1NPC1RAB9A | |
| SCHEMBL18094497 | 0.83 | LSS (0.46) | MAPTADORA3RXFP1MPLLMNA | |
| SCHEMBL18094518 | 0.83 | MPL (0.46) | MAPTADORA3MPLLMNA | |
| SCHEMBL18094454 | 0.83 | SMN1; SMN2 (0.49) | MAPTMPLABL1 | |
| SCHEMBL18094576 | 0.83 | ADORA3 (0.54) | MAPTADORA3RXFP1LMNATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | AVISTA PHARMA SOLUTIONS, INC. | 2017-07-20 | — | — | US | claimed |
| US-9643963-B2 | Antiparasitic compounds | AVISTA PHARMA SOLUTIONS, INC. (US) | 2017-05-09 | — | — | US | claimed |
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | SNAPDRAGON CHEMISTRY, INC. | 2016-09-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | MAPT 2921/4885ADORA3 648/4885RXFP1 4100/4885 |
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | MAPT 2921/4885ADORA3 648/4885RXFP1 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.